

S3 Table. Pooled incidence rate of sustained virological response at weeks 12 and 24 after the end of treatment

Treatment	Pooled SVR12 (95% CI)	Pooled SVR24 (95% CI)
PR	51% (43%, 59%)	48% (40%, 57%)
SMV plus PR	83% (79%, 86%)	83% (80%, 86%)
DCV plus PR	65% (57%, 73%)	62% (53%, 70%)
SOF plus PR	82% (63%, 100%)	81% (68%, 95%)
SOF plus LDV	98% (95%, 100%)	-
SOF plus SMV	97% (90%, 100%)	-
SOF plus DCV	100% (95%, 100%)	96% (88%, 99%)
PrOD	-	89% (79%, 95%)
SOF plus LDV with RBV	97% (95%, 100%)	-
SOF plus SMV with RBV	93% (86%, 100%)	-
SOF plus DCV with RBV	96% (92%, 100%)	95% (85%, 99%)
PrOD with RBV	-	95% (83%, 99%)

CI, confidence interval; DCV, daclatasvir; LDV, ledipasvir; PR, pegylated interferon-ribavirin; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR12, sustained virological response at week 12 after the end of treatment; SVR24, sustained virological response at week 24 after the end of treatment